-
- Vrsta/tip rada: Pregledni (revijski) članak
- PREGLEDAJTE RAD
- PREUZMITE RAD
-
- 27 pregleda
- 53 puta preuzet
Abstract
Introduction. According to the latest studies, glucagon-like peptide-1 receptor agonists, in addition to reducing glycaemia and body weight, also exert strong anti-inflammatory and im munomodulatory effects and are increasingly used to treat chronic inflammatory dermatoses. Glucagon-like peptide-1 receptor agonists and psoriasis vulgaris. In practice, positive effects of glucagon-like peptide-1 receptor agonists on psoriasis severity associated with insulin resistance/diabetes mellitus type 2 and obesity have been observed. In various studies, glucagon like peptide-1 receptor agonists resulted in significant reductions in psoriasis severity scores and improvements in quality of life. Studies have shown significant improvements in clinical picture and quality of life with glucagon-like peptide-1 receptor agonists in patients with hidradenitis suppurativa associated with obesity.
Discussion. Psoriasis and hidradenitis suppurativa are dermatoses characterised by complex immune-mediated inflammatory processes. Clinical studies indicate that the use of glucagon-like peptide-1 receptor agonists leads to improvement of the clinical picture and skin changes in these patients who are obese and have type 2 diabetes/metabolic syndrome.
Conclusion. Due to their metabolic, anti-inflammatory, and immunomodulatory effects, glucagon-like peptide-1 receptor agonists represent a promising therapeutic option for inflammatory dermatoses. Their effects are attributable not solely to weight loss but also to direct immunomodulatory action, which explains their efficacy independent of body weight reduction. Further randomised, placebo-controlled clinical trials are required to confirm their effectiveness.